Table 2.

Drug-Related Treatment-Emergent Adverse Events

	All	Cohort 1	Cohort 2	Cohort 3	Cohort 4	Cohort 5	Cohort 6
	Placebo	Active	Active	Active	Active	Active	Active
System organ class	Subjects	25 mg	50 mg	100 mg	100 mg	100 mg	100 mg
Preferred term	(N = 8)	(N = 6)	(N = 6)	(N = 6)	(N = 6)	(N = 6)	(N = 6)
Subjects with at least one drug-related TEAE	0	3 (50%)	2 (33%)	3 (50%)	1 (17%)	1 (17%)	2 (33%)
Respiratory, thoracic, and mediastinal disorders
Cough	0	1 (17%)	1 (17%)	3 (50%)	1 (17%)	1 (17%)	1 (17%)
Possibly related	0	1 (100%)	0	0	0	0	1 (100%)
Probably related	0	0	1 (100%)	3 (100%)	1 (100%)	1 (100%)	0
Increased upper airway secretion	0	2 (33%)	0	0	0	0	0
Possibly related	0	2 (100%)	0	0	0	0	0
Probably related	0	0	0	0	0	0	0
Dysphonia	0	0	0	0	0	0	1 (17%)
Possibly related	0	0	0	0	0	0	1 (100%)
Probably related	0	0	0	0	0	0	0
Nervous system disorders
Headache	0	0	1 (17%)	0	0	0	1 (17%)
Possibly related	0	0	1 (100%)	0	0	0	1 (100%)
Probably related	0	0	0	0	0	0	0
Dizziness
Possibly related	0	0	1 (100%)	0	0	0	0
Probably related	0	0	0	0	0	0	1 (100%)

Severity was mild in all events with the exception of headache in IPF cohort that was moderate. This event occurred 5 hours after drug was administered and lasted for 2 days. All other related AEs were transient.

TEAE, treatment-emergent adverse event; IPF, idiopathic pulmonary fibrosis; AE, adverse event.